Recently, Qingdao Primedicine Pharmaceutical Technology Co., Ltd. announced that it has successfully completed the preclinical research on two indications of drug addiction and cerebral stroke, and has submitted the research results for pre-investigation of the new drug. It is anticipated that the clinical approval and the subsequent clinical phase I research will be conducted in the second half of 2020.
Recently, Qingdao Primedicine Pharmaceutical Technology Co. Ltd. (hereafter referred as "Primedicine Pharmaceutical") announced that it has obtained the exclusive authorization in China for an innovative polypeptide medicine for treating myocardial infarction from Canada's Primary Peptides Inc (hereafter referred as Primary Peptides).
From January 11th to January 12th, 2020, the first themed 2019 Year-end Meeting team-building activity was held by Qingdao Primedicine Pharmaceutical Technology Co., Ltd. Though the activity lasted only for a day and a half, it left an indelible impression on all employees and increased their camaraderie.
From October 15th–17th, 2019, Qingdao Primedicine Pharmaceutical Technology Co., Ltd., under the arrangements and coordination of Qingdao Municipal Party Committee Organization Department and Municipal Human Resources and Social Security Bureau, participated in the “Famous School Tour of Qingdao Talents Recruitment” (Beijing Recruitment Week) recruitment and promotion program in Beijing.
On July 10th, Wang Yutian, Fellow of The Royal Society of Canada (the Academy of Sciences of Canada), signed a cooperation agreement with Lanpu Biological Technology Co., Ltd. and Beijing UnderProved Medical Technology Co., Ltd. to establish Changchun Lanpu Medical Technology Co., Ltd. The signing ceremony was held in Shangri-La Hotel, Changchun.
Copyright © 2020 Qingdao Primedicine Pharmaceutical Technology Co., Ltd. All right reserved
